Feeding IC 342: The nuclear spiral of a starburst galaxy

IC 342 is a large nearby (1.8 Mpc, Turner and Hurt, 1991, hereafter T&H) spiral galaxy undergoing a moderate nuclear starburst. T&H have previously mapped the inner arcminute in CO-13(1-0) using the Owens Valley Millimeter Interferometer and found evidence that the nuclear molecular gas takes the form of spiral arms in a density wave pattern. They suggest that radial streaming along the arms may channel gas from the exterior of the galaxy into the nucleus, feeding the starburst. We have mapped the CO-12(1-0) emission of the inner 2 kpc of IC 342 at 2.8 inch resolution using the Owens Valley Radio Observatory (OVRO) Millimeter Interferometer. The greater sensitivity of CO-12 observations has allowed us to trace the spiral pattern out to a total extent of greater than 1 kpc. The CO-12 observations extend considerably the structure observed at CO-13 and offer further evidence that a spiral density wave may extend from the disk into the nucleus of IC 342

Is a local bar a good place to find a companion? The near infrared morphology of Maffei 2

Maffei 2 is one of the closest large spiral galaxies lying just beyond the Local Group. It would probably be one of the most heavily studied galaxies in the sky were it not for the approximately 5 magnitudes of visual extinction resulting from its position behind the Galactic plane. It is the site of a burst of nuclear star formation indicated by strong infrared and radii continuum emission. Interferometric maps of CO-12 and CO-13 emission indicate that star formation is associated with a barlike structure consisting of arms of molecular gas that extend from within approximately 50 pc of the dynamical center out to a radius of at least 500 pc. HI maps have shown the galaxy to have an angular extent of approximately 15 feet and a neutral gas mass typical of a large spiral galaxy

Extended Molecular Gas in the Nearby Starburst Galaxy Maffei 2

We present a 9'x9' fully-sampled map of the CO J=1-0 emission in the nearby starburst galaxy Maffei 2 obtained at the Five College Radio Astronomy Observatory. The map reveals previously known strong CO emission in the central starburst region as well as an extended asymmetric distribution with bright CO lines at the ends of the bar and in a feature at the north-east edge of the molecular disk. This northern feature, proposed previously to be an interacting companion galaxy, could be a dwarf irregular galaxy, although the CO data are also consistent with the feature being simply an extension of one of the spiral arms. We estimate the total molecular gas mass of Maffei 2 to be (1.4-1.7)x10^9 Mo or ~3-4% of its dynamical mass. Adopting the recently determined lower value for the CO-to-H2 conversion factor in the central region, our data lead to the surprising result that the largest concentrations of molecular gas in Maffei 2 lie at the bar ends and in the putative dwarf companion rather than in the central starburst. A gravitational stability analysis reveals that the extended disk of Maffei 2 lies above the critical density for star formation; however, whether the central region is also gravitationally unstable depends both on the details of the rotation curve and the precise value of the CO-to-H2 conversion factor in this region.Comment: accepted to ApJ (Sept 10 2004 issue

Barriers to reporting non-motor symptoms to health-care providers in people with Parkinson's

Background: Non-motor symptoms (NMS) are common in Parkinson's disease (PD) and cause significant distress. A high rate of non-declaration of NMS by patients to healthcare providers (HCP) means that many NMS remain untreated. Current understanding of the factors preventing disclosure of NMS to HCPs is limited. The present study aimed to i) further assess the prevalence of NMS and associated distress, ii) establish current rates of NMS reporting across a range of sources, and iii) explore overall and any symptom specific barriers to help-seeking for NMS. Methods: 358 PD patients completed a cross-sectional survey of NMS severity, reporting and barriers to help-seeking. A series of Generalised Estimating Equations were used to determine whether barriers were symptom specific. Results: A mean of 10.5 NMS were reported by each patient. Rates of non-reporting of NMS ranged from 15 to 72% of those experiencing distressing symptoms. The most commonly reported barriers to help-seeking were acceptance of symptoms; lack of awareness that a symptom was associated with PD, and belief that no effective treatments were available. Symptom specific barriers were found for sexual dysfunction (embarrassment), unexplained pain and urinary problems (belief about lack of treatment availability). Conclusion: A diverse range of barriers prevent PD patients reporting NMS to HCPs and these barriers differ between NMS. The study provides the foundations for developing interventions to increase reporting by targeting individual NMS. Increasing rates of help-seeking for NMS by patients to their Parkinson's healthcare providers will increase appropriate clinical care which may improve quality of life and well-being

ARE ECONOMIC FUNDAMENTALS DRIVING FARMLAND VALUES?

Farmland, Land Value, Agricultural Finance, Land Economics/Use, Q14, Q15,

Prioritising target non-pharmacological interventions for research in Parkinson’s Disease: Achieving consensus from key stakeholders

Background: In 2014 Parkinson’s UK conducted a research prioritisation exercise with stakeholders highlighting important clinical research questions. The exercise highlighted the need for effective interventions to be developed and tested to tackle a range of non-motor symptoms including: sleep quality, stress and anxiety, mild cognitive impairment, dementia and urinary problems. The present work set out to build on this exercise by prioritising types of non-pharmacological interventions to be tested to treat the identified non-motor symptoms. Methods: A Patient and Public Involvement Exercise was used to reach consensus on intervention priorities for the treatment on non-motor symptoms. Some Delphi techniques were also used to support the feedback collected. A first-round prioritisation survey was conducted followed by a panel discussion. Nineteen panellists completed the first-round survey (9 people with Parkinson’s and 10 professionals working in Parkinson’s) and 16 participated in the panel discussion (8 people with Parkinson’s and 8 professionals working in Parkinson’s). A second-round prioritization survey was conducted after the panel discussion with 13 people with Parkinson’s. Results: Physical activity, third wave cognitive therapies and cognitive training were rated as priority interventions for the treatment of a range of non-motor symptoms. There was broad agreement on intervention priorities between health care professionals and people with Parkinson’s. A consensus was reached that research should focus on therapies which could be used to treat several different non-motor symptoms. In the context of increasing digitisation, the need for human interaction as an intervention component was highlighted.3 Conclusion: Bringing together Parkinson’s professionals and people with Parkinson’sresulted in a final treatment priority list which should be both feasible to carry out in routine clinical practice and acceptable to both professionals and people with Parkinson’s. The workshop further specified research priorities in Parkinson’s disease based on the current evidence base, stakeholder preferences, and feasibility. Research should focus on developing and testing non-pharmacological treatments which could be effective across a range of symptoms but specifically focusing on tailored physical activity interventions, cognitive therapies and cognitive training

Clinical significance of Polycomb gene expression in brain tumors

Polycomb group (PcG) proteins are crucial for neural cancer stem cell (NCSC) self-renewal. However, the relative expression levels of PcG genes in different subtypes of brain tumors, their prognostic role and their effects on cellular pathways have not been investigated. For this purpose, we queried the Oncomine database and found that 4 PcG genes (EZH2, RBBP7, SUZ12, YY1) are specifically expressed in brain tumors. EZH2 expression increases with tumor grade in adult and pediatric brain tumors, and is a poor prognostic factor. In glioblastoma, EZH2 inhibits differentiation, and activates cancer-, cell cycle- and cellular movement-related genes. In keeping with previously published data, our results suggest that EZH2 is both a prognostic factor and a promising therapy target in brain tumors